NiliMedix ^{For Profit}

Established in 2002, NiliMEDIX Ltd. is a medical device company committed to developing safer, easier to use and more economic tools for Continuous Subcutaneous Insulin Infusion (CSII) for people with Diabetes. The NiliMEDIX patent-protected platform technology is based on a proprietary pressure triggered release mechanism, controlled by a unique valves and sensors system. NiliMEDIX and its associate companies are involved in developing technologies aimed at safer drug delivery as well as innovative measures for the most accurate Continuous Glucose Monitoring (CGM). Based on its core technology, the company has developed the ADI Insulin Pump, that has already received the CE-Mark and was FDA cleared, allowing its marketing both in the EU countries and in the US. Following this first generation product, the company will soon launch its first single-use insulin pump.